Loading…
Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice
. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 200...
Saved in:
| Published in: | Rheumatology 2015-04, Vol.54 (4), p.672-677 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453 |
| container_end_page | 677 |
| container_issue | 4 |
| container_start_page | 672 |
| container_title | Rheumatology |
| container_volume | 54 |
| creator | Fortunet, Clémentine Pers, Yves-Marie Lambert, Joseph Godfrin-Valnet, Marie Constant, Elodie Devilliers, Hervé Gaudin, Philippe Jorgensen, Christian Prades, Béatrice Pallot Wendling, Daniel Maillefert, Jean Francis |
| description | . The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.
This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the dose of CS.
Inclusion of 130 patients [women 80.8%, mean age 56.7 years (s.d. 14.0), RA duration 16.3 years (s.d. 10.4), mean baseline 28-joint DAS (DAS28) 5.1 (s.d. 1.4), mean baseline dose of CS 10.0 mg/day (s.d. 8.2) prednisone equivalent. Decreases in the mean daily dose of CS and in the DAS28 were observed during follow-up [respectively 6.5 mg (s.d. 4.8) at week 24 (P < 0.0001) and 3.0 mg (s.d. 1.4) at week 24 (P < 0.0001)]. The only variable that correlated with the decrease in the dose of CS was the initial dose of the drug (r = 0.82, P < 0.001).
The introduction of TCZ led to rapid and long-lasting CS sparing that did not correlate with the reduction in disease activity. It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity. |
| doi_str_mv | 10.1093/rheumatology/keu339 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01303534v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1667352159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453</originalsourceid><addsrcrecordid>eNpNkU1PwzAMhiMEYjD4BUioRzgUkjjpxxEhvqRJXOAc3DTdAl1TkhQJfj2dOiZOtuzHry2_hJwxesVoCdd-ZYY1Rte65ff1hxkAyj1yxETGUwrA93c5FzNyHMI7pVQyKA7JjEsuskzQI_L24rRt7c-oVCW2qwdtQqKdj1a7EI13tk5Cj952y7Gd_O0cq-jjyttoQ9JjtKaLYQPo1nZWY5v0HvUoYk7IQYNtMKfbOCev93cvt4_p4vnh6fZmkerx7phmXOYNVIhQyrKQmPPCaChA15mUQHNR0oZhiVmVV3XDhZEoNWoqoC4QhYQ5uZx0V9iq3ts1-m_l0KrHm4Xa1CgDChLEFxvZi4ntvfscTIhqbYM2bYudcUNQLMtykJzJckRhQrV3IXjT7LQZVRsb1H8b1GTDOHW-XTBUa1PvZv7-Dr8cOonb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1667352159</pqid></control><display><type>article</type><title>Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Fortunet, Clémentine ; Pers, Yves-Marie ; Lambert, Joseph ; Godfrin-Valnet, Marie ; Constant, Elodie ; Devilliers, Hervé ; Gaudin, Philippe ; Jorgensen, Christian ; Prades, Béatrice Pallot ; Wendling, Daniel ; Maillefert, Jean Francis</creator><creatorcontrib>Fortunet, Clémentine ; Pers, Yves-Marie ; Lambert, Joseph ; Godfrin-Valnet, Marie ; Constant, Elodie ; Devilliers, Hervé ; Gaudin, Philippe ; Jorgensen, Christian ; Prades, Béatrice Pallot ; Wendling, Daniel ; Maillefert, Jean Francis</creatorcontrib><description>. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.
This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the dose of CS.
Inclusion of 130 patients [women 80.8%, mean age 56.7 years (s.d. 14.0), RA duration 16.3 years (s.d. 10.4), mean baseline 28-joint DAS (DAS28) 5.1 (s.d. 1.4), mean baseline dose of CS 10.0 mg/day (s.d. 8.2) prednisone equivalent. Decreases in the mean daily dose of CS and in the DAS28 were observed during follow-up [respectively 6.5 mg (s.d. 4.8) at week 24 (P < 0.0001) and 3.0 mg (s.d. 1.4) at week 24 (P < 0.0001)]. The only variable that correlated with the decrease in the dose of CS was the initial dose of the drug (r = 0.82, P < 0.001).
The introduction of TCZ led to rapid and long-lasting CS sparing that did not correlate with the reduction in disease activity. It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>EISSN: 1460-2172</identifier><identifier>DOI: 10.1093/rheumatology/keu339</identifier><identifier>PMID: 25246640</identifier><language>eng</language><publisher>England: Oxford University Press (OUP)</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adult ; Aged ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Drug Therapy, Combination ; Female ; Glucocorticoids - therapeutic use ; Human health and pathology ; Humans ; Life Sciences ; Male ; Medication ; Middle Aged ; Pharmaceutical sciences ; Prednisone - therapeutic use ; Retrospective Studies ; Rhumatology and musculoskeletal system ; Treatment Outcome</subject><ispartof>Rheumatology, 2015-04, Vol.54 (4), p.672-677</ispartof><rights>The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453</citedby><cites>FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453</cites><orcidid>0000-0002-4687-5780 ; 0000-0001-5927-3773 ; 0000-0003-0679-1029 ; 0000-0001-6947-8094</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25246640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://u-bourgogne.hal.science/hal-01303534$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Fortunet, Clémentine</creatorcontrib><creatorcontrib>Pers, Yves-Marie</creatorcontrib><creatorcontrib>Lambert, Joseph</creatorcontrib><creatorcontrib>Godfrin-Valnet, Marie</creatorcontrib><creatorcontrib>Constant, Elodie</creatorcontrib><creatorcontrib>Devilliers, Hervé</creatorcontrib><creatorcontrib>Gaudin, Philippe</creatorcontrib><creatorcontrib>Jorgensen, Christian</creatorcontrib><creatorcontrib>Prades, Béatrice Pallot</creatorcontrib><creatorcontrib>Wendling, Daniel</creatorcontrib><creatorcontrib>Maillefert, Jean Francis</creatorcontrib><title>Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice</title><title>Rheumatology</title><addtitle>Rheumatology (Oxford)</addtitle><description>. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.
This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the dose of CS.
Inclusion of 130 patients [women 80.8%, mean age 56.7 years (s.d. 14.0), RA duration 16.3 years (s.d. 10.4), mean baseline 28-joint DAS (DAS28) 5.1 (s.d. 1.4), mean baseline dose of CS 10.0 mg/day (s.d. 8.2) prednisone equivalent. Decreases in the mean daily dose of CS and in the DAS28 were observed during follow-up [respectively 6.5 mg (s.d. 4.8) at week 24 (P < 0.0001) and 3.0 mg (s.d. 1.4) at week 24 (P < 0.0001)]. The only variable that correlated with the decrease in the dose of CS was the initial dose of the drug (r = 0.82, P < 0.001).
The introduction of TCZ led to rapid and long-lasting CS sparing that did not correlate with the reduction in disease activity. It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medication</subject><subject>Middle Aged</subject><subject>Pharmaceutical sciences</subject><subject>Prednisone - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rhumatology and musculoskeletal system</subject><subject>Treatment Outcome</subject><issn>1462-0324</issn><issn>1462-0332</issn><issn>1460-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpNkU1PwzAMhiMEYjD4BUioRzgUkjjpxxEhvqRJXOAc3DTdAl1TkhQJfj2dOiZOtuzHry2_hJwxesVoCdd-ZYY1Rte65ff1hxkAyj1yxETGUwrA93c5FzNyHMI7pVQyKA7JjEsuskzQI_L24rRt7c-oVCW2qwdtQqKdj1a7EI13tk5Cj952y7Gd_O0cq-jjyttoQ9JjtKaLYQPo1nZWY5v0HvUoYk7IQYNtMKfbOCev93cvt4_p4vnh6fZmkerx7phmXOYNVIhQyrKQmPPCaChA15mUQHNR0oZhiVmVV3XDhZEoNWoqoC4QhYQ5uZx0V9iq3ts1-m_l0KrHm4Xa1CgDChLEFxvZi4ntvfscTIhqbYM2bYudcUNQLMtykJzJckRhQrV3IXjT7LQZVRsb1H8b1GTDOHW-XTBUa1PvZv7-Dr8cOonb</recordid><startdate>201504</startdate><enddate>201504</enddate><creator>Fortunet, Clémentine</creator><creator>Pers, Yves-Marie</creator><creator>Lambert, Joseph</creator><creator>Godfrin-Valnet, Marie</creator><creator>Constant, Elodie</creator><creator>Devilliers, Hervé</creator><creator>Gaudin, Philippe</creator><creator>Jorgensen, Christian</creator><creator>Prades, Béatrice Pallot</creator><creator>Wendling, Daniel</creator><creator>Maillefert, Jean Francis</creator><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4687-5780</orcidid><orcidid>https://orcid.org/0000-0001-5927-3773</orcidid><orcidid>https://orcid.org/0000-0003-0679-1029</orcidid><orcidid>https://orcid.org/0000-0001-6947-8094</orcidid></search><sort><creationdate>201504</creationdate><title>Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice</title><author>Fortunet, Clémentine ; Pers, Yves-Marie ; Lambert, Joseph ; Godfrin-Valnet, Marie ; Constant, Elodie ; Devilliers, Hervé ; Gaudin, Philippe ; Jorgensen, Christian ; Prades, Béatrice Pallot ; Wendling, Daniel ; Maillefert, Jean Francis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medication</topic><topic>Middle Aged</topic><topic>Pharmaceutical sciences</topic><topic>Prednisone - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rhumatology and musculoskeletal system</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fortunet, Clémentine</creatorcontrib><creatorcontrib>Pers, Yves-Marie</creatorcontrib><creatorcontrib>Lambert, Joseph</creatorcontrib><creatorcontrib>Godfrin-Valnet, Marie</creatorcontrib><creatorcontrib>Constant, Elodie</creatorcontrib><creatorcontrib>Devilliers, Hervé</creatorcontrib><creatorcontrib>Gaudin, Philippe</creatorcontrib><creatorcontrib>Jorgensen, Christian</creatorcontrib><creatorcontrib>Prades, Béatrice Pallot</creatorcontrib><creatorcontrib>Wendling, Daniel</creatorcontrib><creatorcontrib>Maillefert, Jean Francis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fortunet, Clémentine</au><au>Pers, Yves-Marie</au><au>Lambert, Joseph</au><au>Godfrin-Valnet, Marie</au><au>Constant, Elodie</au><au>Devilliers, Hervé</au><au>Gaudin, Philippe</au><au>Jorgensen, Christian</au><au>Prades, Béatrice Pallot</au><au>Wendling, Daniel</au><au>Maillefert, Jean Francis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice</atitle><jtitle>Rheumatology</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2015-04</date><risdate>2015</risdate><volume>54</volume><issue>4</issue><spage>672</spage><epage>677</epage><pages>672-677</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><eissn>1460-2172</eissn><abstract>. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.
This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the dose of CS.
Inclusion of 130 patients [women 80.8%, mean age 56.7 years (s.d. 14.0), RA duration 16.3 years (s.d. 10.4), mean baseline 28-joint DAS (DAS28) 5.1 (s.d. 1.4), mean baseline dose of CS 10.0 mg/day (s.d. 8.2) prednisone equivalent. Decreases in the mean daily dose of CS and in the DAS28 were observed during follow-up [respectively 6.5 mg (s.d. 4.8) at week 24 (P < 0.0001) and 3.0 mg (s.d. 1.4) at week 24 (P < 0.0001)]. The only variable that correlated with the decrease in the dose of CS was the initial dose of the drug (r = 0.82, P < 0.001).
The introduction of TCZ led to rapid and long-lasting CS sparing that did not correlate with the reduction in disease activity. It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity.</abstract><cop>England</cop><pub>Oxford University Press (OUP)</pub><pmid>25246640</pmid><doi>10.1093/rheumatology/keu339</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4687-5780</orcidid><orcidid>https://orcid.org/0000-0001-5927-3773</orcidid><orcidid>https://orcid.org/0000-0003-0679-1029</orcidid><orcidid>https://orcid.org/0000-0001-6947-8094</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology, 2015-04, Vol.54 (4), p.672-677 |
| issn | 1462-0324 1462-0332 1460-2172 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01303534v1 |
| source | Oxford Journals Online; Alma/SFX Local Collection |
| subjects | Adrenal Cortex Hormones - therapeutic use Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Drug Therapy, Combination Female Glucocorticoids - therapeutic use Human health and pathology Humans Life Sciences Male Medication Middle Aged Pharmaceutical sciences Prednisone - therapeutic use Retrospective Studies Rhumatology and musculoskeletal system Treatment Outcome |
| title | Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tocilizumab%20induces%20corticosteroid%20sparing%20in%20rheumatoid%20arthritis%20patients%20in%20clinical%20practice&rft.jtitle=Rheumatology&rft.au=Fortunet,%20Cl%C3%A9mentine&rft.date=2015-04&rft.volume=54&rft.issue=4&rft.spage=672&rft.epage=677&rft.pages=672-677&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keu339&rft_dat=%3Cproquest_hal_p%3E1667352159%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c339t-6257f3baa395985a728ec383cd655307490f1a9a6b7bdf24e5a5cac043d8aa453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1667352159&rft_id=info:pmid/25246640&rfr_iscdi=true |